Notably, administering the PPT1 inhibitor hexadecylsulfonylfluoride (HDSF) to both healthy volunteers and SLE patients reduces IFNα production ex vivo, underscoring its therapeutic potential for autoimmune diseases. The gene discussed is PPT1; the disease is systemic lupus erythematosus.